| Literature DB >> 31752812 |
Nabilah Mohammad Yaqoob Akhtar1, Ibrahim Jantan2, Laiba Arshad3, Md Areeful Haque4.
Abstract
BACKGROUND: Zingiber zerumbet rhizome and its bioactive metabolites have previously been reported to exhibit innumerable pharmacological properties particularly anti-inflammatory activities. In the present study, the 80% ethanol extract, essential oil and zerumbone of Z. zerumbet rhizomes were explored for their in vitro immunosuppressive properties on chemotaxis, CD11b/CD18 expression, phagocytosis and chemiluminescence of isolated human polymorphonuclear neutrophils (PMNs).Entities:
Keywords: Essential oil; Human neutrophils; Immunosuppressive effects; Phagocytic activity; Zerumbone; Zingiber zerumbet
Mesh:
Substances:
Year: 2019 PMID: 31752812 PMCID: PMC6873536 DOI: 10.1186/s12906-019-2748-5
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Fig. 1Chemical structure of zerumbone
Fig. 213C NMR spectrum of zerumbone
Percentage composition of essential oil of Zingiber zerumbet
| Compound | Percentage composition (%) | Kovat Indexc | Method of Identification |
|---|---|---|---|
| α-Pinene | 1.27 | 939 | a,b,c |
| Camphene | 5.36 | 957 | a,b,c |
| α-Terpinene | 0.36 | 1018 | a,b,c |
| 1,8-Cineole | 1.70 | 1032 | a,b,c |
| β-Ocimene | 1.46 | 1038 | a,b, |
| Nonen-1-ol | 1.75 | 1158 | a,b, |
| Terpinen-4-ol | 1.53 | 1178 | a,b,c |
| β-Caryophyllene | 0.92 | 1420 | a,b,c |
| α-Humulene | 12.24 | 1458 | a,b,c |
| (E)-Nerolidol | 1.44 | 1564 | a,b |
| Caryophyllene oxide | 2.05 | 1581 | a,b |
| Humulene epoxide | 4.96 | 1608 | a,b |
| Caryophylla-4 (14),8 (15)-dien-5.alpha.-ol | 3.86 | 1642 | a,b |
| Calamenene | 0.49 | 1662 | a,b |
| α-Bisabolol | 1.03 | 1674 | a,b |
| Farnesol | 0.81 | 1708 | a,b |
| Zerumbone | 58.44 | 1734 | a,b,c |
a: analysis by mass fragmentation pattern in gas chromatography mass spectrometry (GC-MS)
b: Kovat indices on a DB5 column (1 μm thickness, 30.0 m length, 0.25 mm diameter)
c: co-chromatography with authentic sample
Fig. 3Percentage inhibition of test samples on PMN chemotaxis presented as mean ± SEM (n = 3). Data were analyzed by one-way ANOVA followed by Dunnet’s post hoc test. Significance of differences with respect to control: *p < 0.05
Percentage of CD11b/CD18 expression activity (%) of neutrophils at different concentrations of test samples derived from Zingiber zerumbet
| Sample (μg/mL) | Concentration (μg/mL) | ||
|---|---|---|---|
| 50 | 12.5 | 3.13 | |
| 87.67 ± 0.59 | 89.80 ± 0.66 | 96.23 ± 1.63 | |
| 91.03 ± 0.63 | 92.93 ± 1.45 | 96.10 ± 0.85 | |
| Zerumbone (ZER) | 72.57 ± 6.45* | 76.47 ± 4.80* | 86.77 ± 1.77 |
| Positive control | 92.47 ± 3.38 | ||
Data are presented as mean ± SEM, n = 3. Data were analyzed by one-way ANOVA followed by Dunnet’s post hoc test. Significance of differences with respect to control: *p < 0.05
Fig. 4CD11b/CD18 expression activity by neutrophils treated with test samples i.e., (a) positive control, (b) Z. zerumbet extract (50 μg/mL), (c) Z. zerumbet essential oil (50 μg/mL), (d) zerumbone (10 μg/mL)
Percentage of phagocytic activity (%) of neutrophils at different concentrations of test samples derived from Zingiber zerumbet
| Sample (μg/mL) | Concentration (μg/mL) | ||
|---|---|---|---|
| 50 | 12.5 | 3.13 | |
| 55.43 ± 0.77* | 58.50 ± 1.15* | 59.30 ± 0.68* | |
| 69.20 ± 0.74* | 70.83 ± 1.48* | 77.87 ± 1.18* | |
| Zerumbone (ZER) | 76.97 ± 1.15* | 77.73 ± 2.48* | 79.70 ± 3.08* |
| Positive control | 93.03 ± 1.56 | ||
Data are presented as mean ± SEM, n = 3. Data were analyzed by one-way ANOVA followed by Dunnet’s post hoc test. Significance of differences with respect to control: *p < 0.05
Fig. 5E. coli engulfment by neutrophils treated with test samples i.e., (a) negative control, (b) positive control, (c) Z. zerumbet extract (50 μg/mL), (d) Z. zerumbet essential oil (50 μg/mL), (e) zerumbone (10 μg/mL)
IC50 values (μg/mL) of ROS inhibitory activity of tested samples on human whole blood and PMNs
| Samples | Zymosan | PMA | ||
|---|---|---|---|---|
| Whole blood | PMNs | Whole blood | PMNs | |
| 6.49 ± 2.16 | 2.89 ± 0.98 | 10.87 ± 1.50 | 14.87 ± 2.70*** | |
| 8.71 ± 1.37* | 5.88 ± 1.70 | 11.63 ± 1.78 | 12.62 ± 0.87** | |
| Zerumbone (ZER) | – | 8.25 ± 0.73* (37.77 ± 3.38) | 6.83 ± 0.68 (31.25 ± 3.10) | 3.79 ± 0.24 (17.36 ± 1.08) |
| Aspirin | 2.63 ± 0.17 (14.57 ± 0.92) | 1.95 ± 0.07 (10.82 ± 0.40) | 7.65 ± 0.43 (42.46 ± 2.40) | 2.94 ± 0.26 (16.30 ± 1.46) |
Data are presented as (mean ± SEM, n = 3). Data were analyzed by one-way ANOVA followed by Dunnet’s post hoc test. IC50 values in μM are shown in parentheses. Significance of differences with respect to control: *p < 0.05, ** p < 0.01, ***p < 0.001